Last reviewed · How we verify
dexmedetomidine infusion group
Dexmedetomidine, marketed by Yeungnam University College of Medicine, is an infusion therapy currently available in the market. The key composition patent for dexmedetomidine is set to expire in 2028, providing a period of exclusivity that supports its market position. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | dexmedetomidine infusion group |
|---|---|
| Also known as | Precedex, Precedex infusion, Dexmedetomidine, Precedex injection, Dexmedetomidine hydrochloride 118 mcg/ml |
| Sponsor | Yeungnam University College of Medicine |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Lidocaine Infusion Versus Dexmedemidine Infusion on the Neurocognitive Function of Elderly Patients Undergoing Endoscopic Retrograde Cholangiopancreatography(ERCP): a Randomized, Controlled Trial. (NA)
- The Relationship Between Opioid-Free Anesthesia and Postoperative Agitation-Delirium and Quality of Recovery in Pediatric Ear, Nose, and Throat Cases Monitored With Perioperative Bispectral Index
- Continuous Epidural With Dexmedetomidine Adjuvant in Gynecologic Laparotomy (PHASE4)
- Opioid Free and Opioid Based Anesthesia in Elective Lumbar Spine Surgery
- Safety and Efficacy of Dexmedetomidate vs. Midazolam for Procedural Sedation During Medical Thoracoscopy (PHASE3)
- Using Lidocaine or Dexmedetomidine to Help Control Blood Pressure Spikes From a Tourniquet During Knee Surgery (PHASE2)
- The Effect of Dexmedetomidine Infusion Alone Versus the Combination of Dexmedetomidine and Melatonin on Reduction of Post-operative Delirium (POD) After Open Brain Surgeries (PHASE4)
- The Effects of Dexmedetomidine on Postoperative Cognitive Function in Open Heart Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: